Details:
The first candidate in the VP03 program, new AT2R agonist C106, shows high selectivity for AT2R and good activity in reducing TGFb in human tissue with patent protection to 2041, is ready to enter a phase 1 trial.
Lead Product(s): CAS 138564-60-0
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: VP03
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Emeriti Bio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2022
Details:
The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid. Lead candidate PulmoStem™, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic.
Lead Product(s): PulmoStem
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PulmoStem
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $6.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 12, 2021
Details:
The agreement focuses on the development of an inhalation formulation as well as an inhalation product for phase I studies for Respiratorius drug candidate RES030-085 within the RESP9000 project for the treatment of COPD and severe asthma.
Lead Product(s): RES030-085
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RES030-085
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.3 million Upfront Cash: Undisclosed
Deal Type: Agreement May 20, 2021
Details:
Administration of clinically relevant oral doses of VP01 in the so called Sugen-Hypoxia-induced pulmonary hypertension model in rats caused a significant and therapeutically meaningful reduction in pulmonary arterial pressure without affecting the systemic blood pressure.
Lead Product(s): VP01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: VP01
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020